

NCT03472508 Raw comparison:

Summary:
CHIA has 16 criteria while your personal folder has 21 criteria
Total found criteria: 15/16
Total not Found: 1/16
Total Extra: 5
This trial is INVALID



╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ CHIA Criteria                                      │ Matching Personal Criteria                         │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ (2)A diagnosis or previous diagnosis of essential  │ （2）A diagnosis or previous diagnosis of          │
│ hypertension including anyone currently taking     │ essential hypertension including anyone currently  │
│ antihypertensive drugs or for those who have not   │ taking antihypertensive drugs or for those who     │
│ taken antihypertensive drugs within the last 2     │ have not taken antihypertensive drugs within the   │
│ weeks two consecutive examinations were conducted  │ last 2 weeks two consecutive examinations were     │
│ at least one day apart and both sitting blood      │ conducted at least one day apart and both sitting  │
│ pressure (mean value of 3 measurements) met the    │ blood pressure (mean value of 3 measurements) met  │
│ following criteria diastolic blood pressure (DBP)  │ the following criteria diastolic blood pressure    │
│ =90 mmHg or systolic blood pressure (SBP) =140     │ (DBP) ≥90 mmHg or systolic blood pressure (SBP)    │
│ mmHg (the second blood pressure was measured at    │ ≥140 mmHg (the second blood pressure was measured  │
│ V1)                                                │ at V1)                                             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ (3)If a study participant is a woman of            │ （3）If a study participant is a woman of          │
│ childbearing age she agrees to use a reliable      │ childbearing age she agrees to use a reliable      │
│ contraceptive method during the trial              │ contraceptive method during the trial              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ (4)Voluntarily participates and has signed an      │ （4）Voluntarily participates and has signed an    │
│ informed consent form                              │ informed consent form                              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ (1)Completed MTHFR C677T gene polymorphism         │ （1）Completed MTHFR C677T gene polymorphism       │
│ detection in run-in period or MTHFR C677T genotype │ detection in run-in period or MTHFR C677T genotype │
│ already known in advance                           │ already known in advance                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ (2)Exhibited good tolerance to enalapril and good  │ （2）Exhibited good tolerance to enalapril and     │
│ overall medication compliance (>80%) in run-in     │ good overall medication compliance (\>80%) in run- │
│ period or previously exhibited good tolerance and  │ in period or previously exhibited good tolerance   │
│ adherence to ACEI drugs in previous medication     │ and adherence to ACEI drugs in previous medication │
│ history                                            │ history                                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ (3)Voluntarily continues to participate in this    │ （3）Voluntarily continues to participate in this  │
│ study                                              │ study                                              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ (1)Women who are pregnant and/or lactating or      │ （1）Women who are pregnant and/or lactating or    │
│ women who intend to conceive within a year         │ women who intend to conceive within a year         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ (2)History of allergies to enalapril folic acid or │ （2）History of allergies to enalapril folic acid  │
│ other components of the compound drug              │ or other components of the compound drug           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ (3)History of adverse reactions or intolerance to  │ （3）History of adverse reactions or intolerance   │
│ enalapril or other ACE inhibitors or drugs or      │ to enalapril or other ACE inhibitors or drugs or   │
│ supplements containing folic acid                  │ supplements containing folic acid                  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ (4)Diagnosis or suspicion of secondary             │ （4）Diagnosis or suspicion of secondary           │
│ hypertension                                       │ hypertension                                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ (5)Known serious medical conditions including      │ （5）Known serious medical conditions including    │
│ Cardiovascular patients with clinically diagnosed  │ Cardiovascular patients with clinically diagnosed  │
│ cardiac dysfunction (NYHA class III and above)     │ cardiac dysfunction (NYHA class III and above)     │
│ hypertrophic obstructive cardiomyopathy clinically │ hypertrophic obstructive cardiomyopathy clinically │
│ significant valvular heart disease acute coronary  │ significant valvular heart disease acute coronary  │
│ syndrome within the last 3 months or percutaneous  │ syndrome within the last 3 months or percutaneous  │
│ coronary intervention (PCI) or coronary artery     │ coronary intervention (PCI) or coronary artery     │
│ bypass graft (CABG) or abnormal pre-enrollment ECG │ bypass graft (CABG) or abnormal pre-enrollment ECG │
│ test results with clinically significant           │ test results with clinically significant           │
│ arrhythmias (atrial flutter atrial fibrillation    │ arrhythmias (atrial flutter atrial fibrillation    │
│ grade II-III atrioventricular block etc )          │ grade II-III atrioventricular block etc )          │
│ Digestive a previous diagnosis of various types of │ Digestive a previous diagnosis of various types of │
│ viral hepatitis that are still in the active phase │ viral hepatitis that are still in the active phase │
│ abnormal pre-enrollment liver function test        │ abnormal pre-enrollment liver function test        │
│ results (ALT AST GGT TBIL or DBIL 3 times higher   │ results (ALT AST GGT TBIL or DBIL 3 times higher   │
│ than normal ALB = 30g/L) gastrectomy and/or        │ than normal ALB ≤ 30g/L) gastrectomy and/or        │
│ gastrojejunostomy gastrointestinal dysfunction     │ gastrojejunostomy gastrointestinal dysfunction     │
│ Urinary pre-enrollment serum creatinine greater    │ Urinary pre-enrollment serum creatinine greater    │
│ than 200umol/L clinical diagnosis of renal artery  │ than 200μmol/L clinical diagnosis of renal artery  │
│ stenosis isolated kidney kidney transplantation    │ stenosis isolated kidney kidney transplantation    │
│ and/or other diseases Endocrine type 1 diabetes or │ and/or other diseases Endocrine type 1 diabetes or │
│ uncontrolled type 2 diabetes (fasting blood        │ uncontrolled type 2 diabetes (fasting blood        │
│ glucose above 11 1 mmol/L at pre-enrollment)       │ glucose above 11 1 mmol/L at pre-enrollment)       │
│ previous diagnosis of hyperthyroidism and failure  │ previous diagnosis of hyperthyroidism and failure  │
│ to correct Respiratory pulmonary heart disease     │ to correct Respiratory pulmonary heart disease     │
│ chronic obstructive pulmonary disease              │ chronic obstructive pulmonary disease              │
│ Neuropsychiatric recent transient ischemic attack  │ Neuropsychiatric recent transient ischemic attack  │
│ or stroke (within the last 3 months) peripheral or │ or stroke (within the last 3 months) peripheral or │
│ severe autonomic dysfunction mental or nervous     │ severe autonomic dysfunction mental or nervous     │
│ system dysfunction inability to express desire     │ system dysfunction inability to express desire     │
│ known drug or alcohol dependence Malignancy        │ known drug or alcohol dependence Malignancy        │
│ malnutrition hematopoietic disorders and other     │ malnutrition hematopoietic disorders and other     │
│ serious diseases                                   │ serious diseases                                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ (6)Significant signs of abnormalities as seen in   │ （6）Significant signs of abnormalities as seen in │
│ laboratory tests or physical characteristics which │ laboratory tests or physical characteristics which │
│ at the discretion of the investigators indicates   │ at the discretion of the investigators indicates   │
│ that the patient is experiencing a serious illness │ that the patient is experiencing a serious illness │
│ or may affect the observation and evaluation of    │ or may affect the observation and evaluation of    │
│ the drug's efficacy or adverse events or renders   │ the drug's efficacy or adverse events or renders   │
│ the patient unsuitable for participating in this   │ the patient unsuitable for participating in this   │
│ study                                              │ study                                              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ (7)Patients currently taking folate B12 or B6 or   │ （7）Patients currently taking folate B12 or B6 or │
│ any compounds containing them who express an       │ any compounds containing them who express an       │
│ inability or a refusal to stop usage               │ inability or a refusal to stop usage               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ (8)Regular usage of folic acid supplements or      │ （8）Regular usage of folic acid supplements or    │
│ compounds containing folic acid in the past 3      │ compounds containing folic acid in the past 3      │
│ months                                             │ months                                             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ (9)Participation in a clinical trial for a drug    │ （9）Participation in a clinical trial for a drug  │
│ that has not yet been officially approved for      │ that has not yet been officially approved for      │
│ marketing within one month prior to the first      │ marketing within one month prior to the first      │
│ visit                                              │ visit                                              │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛



╒═══════════════════════════════════════╕
│ CHIA Criteria Not Found in Personal   │
╞═══════════════════════════════════════╡
│ (1)= 45 years old                     │
╘═══════════════════════════════════════╛



╒══════════════════════════════════════════════════════════════════════════════════════╕
│ Extra Personal Criteria                                                              │
╞══════════════════════════════════════════════════════════════════════════════════════╡
│ （1）≥ 45 years old                                                                  │
├──────────────────────────────────────────────────────────────────────────────────────┤
│ Participants meeting any of the following criteria may not participate in this study │
├──────────────────────────────────────────────────────────────────────────────────────┤
│ Must have minimum age of 45 Years                                                    │
├──────────────────────────────────────────────────────────────────────────────────────┤
│ Inclusion Criteria for Double-Blind Treatment Period                                 │
├──────────────────────────────────────────────────────────────────────────────────────┤
│ for run-in period                                                                    │
╘══════════════════════════════════════════════════════════════════════════════════════╛